Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma

被引：7

作者：

Bansal, Radhika ^{[1
]}

Paludo, Jonas ^{[2
]}

Corraes, Andre ^{[2
]}

Spychalla, Megan ^{[2
]}

Haugen, Kelsey ^{[2
]}

Khurana, Arushi ^{[2
]}

Hampel, Paul J. ^{[2
]}

Durani, Urshila ^{[3
]}

Dingli, David ^{[2
]}

Hayman, Suzanne R. ^{[2
]}

Kapoor, Prashant ^{[2
]}

Wang, Yucai ^{[3
]}

Binder, Moritz ^{[2
]}

Kenderian, Saad S. ^{[3
]}

Kourelis, Taxiarchis ^{[3
]}

Kumar, Shaji Kunnathu ^{[3
]}

Warsame, Rahma M. ^{[4
]}

Bennani, N. Nora ^{[2
]}

Gertz, Morie A. ^{[5
]}

Johnston, Patrick B. ^{[3
]}

Ansell, Stephen M. ^{[3
]}

Lin, Yi ^{[1
]}

机构：

[1] Mayo Clin, Canc Ctr, Rochester, MN USA

[2] Mayo Clin, Rochester, MN USA

[3] Mayo Clin, Div Hematol, Rochester, MN USA

[4] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

[5] Mayo Clin, Div Hematol, Dept Med, Rochester, MN USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187186

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] Pseudoprogression in multiple myeloma patients treated with Anti-BCMA CAR-T cells
Topp, Max
Schimanski, Sven
Hornburger, Hannah
Kadel, Sophie
Einsele, Hermann
Rasche, Leo
Duell, Johannes
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 146 - 146
[32] Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma
Reyes, Kevin R.
Huang, Chiung-Yu
Lo, Mimi
Arora, Shagun
Chung, Alfred
Wong, Sandy W.
Wolf, Jeffrey
Olin, Rebecca L.
Martin, Thomas
Shah, Nina
Banerjee, Rahul
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (06): : 350 - 355
[33] Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe
Munoz, Beatriz Merchan
Martinez-Roca, Alexandra
Ballestar, Nuria
Gallego, Cristina
Martinez-Cibrian, Nuria
Ortiz-Maldonado, Valentin
Rodriguez-Lobato, Luis Gerardo
Albiol, Nil
Ayora, Pilar
Ramos, Carla
Sanchez-Castanon, Maria
Juan, Manel
Delgado, Julio
Reyner, Jordi Esteve
Urbano-Ispizua, Alvaro
Larrea, Carlos Fernandez de
Fernandez-Aviles, Francesc
BLOOD, 2024, 144 : 7619 - 7620
[34] Monitoring of Anti-BCMA CAR-T Cells and non-CAR-T Immune Subsets in Multiple Myeloma Patients
Venglar, Ondrej
Viera, Hrabcakova
Soucek, Ondrej
Kutejova, Kamila
Mihalyova, Jana
Muronova, Ludmila
Popkova, Tereza
Zihala, David
Sevcikova, Tereza
Broskevicova, Lucie
Hajek, Roman
Folber, Frantisek
Radocha, Jakub
Jelinek, Tomas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S95 - S95
[35] Update on the current and future use of CAR-T to treat multiple myeloma
Gahvari, Zhubin
Brunner, Matthew
Schmidt, Timothy
Callander, Natalie S.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (04) : 493 - 503
[36] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Christopher T. Su
J. Christine Ye
Journal of Hematology & Oncology, 14
[37] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Su, Christopher T.
Ye, J. Christine
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[38] γ-SECRETASE INHIBITORS IMPROVE MULTIPLE MYELOMA BCMA CAR-T THERAPY
不详
CANCER DISCOVERY, 2019, 9 (11) : 1483 - 1483
[39] CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy
Yu, Tong
Jiao, Jian-Hang
Wu, Min-Fei
FRONTIERS IN IMMUNOLOGY, 2025, 16
[40] Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
Szlasa, Wojciech
Dybko, Jaroslaw
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134

← 1 2 3 4 5 →